UPDATE 1-MannKind soars as FDA panel backs its inhaled insulin product

April 2 (Reuters) - MannKind Corp's shares doubled on Wednesday, after an advisory committee to the U.S. health regulator recommended approval of the drug developer's inhaled insulin treatment.

from Reuters: Hot Stocks http://ift.tt/1h2J2f4